a day ago
- SARS-CoV-2 is a relatively easy target for vaccine development due to prior research on SARS and MERS.
- New faster technologies like mRNA, built on years of research, enabled rapid vaccine creation.
- Financial barriers were removed by government and health organization support, allowing parallel production and trials.
- Regulatory agencies used rolling reviews to speed up the approval process without compromising safety.
- A large number of volunteers were readily available, accelerating the trial phase.